Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06704347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06704347 · ClinicalTrials.gov record · last posted 2026-07-29

Safety Study of XT-150 in Participants With ALS

Name: Safety Study of XT-150 in Participants With ALS — clinical trial record (NCT06704347)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorXalud Therapeutics, Inc.

Started2027-03

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150

Protocol amendment history 2 changes detected by DataLookout

2026-07-30

Primary completion pushed: 2027-03 → 2028-06

2026-07-30

Completion pushed: 2027-03 → 2028-06

Trial Details

NCT Number	NCT06704347
Lead Sponsor	Xalud Therapeutics, Inc.
Conditions	Amyotrophic Lateral Sclerosis (ALS)
Enrollment	8 participants
Start Date	2027-03
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-29